The European Medicines Agency (EMA) has extended the scope of its investigation into the risk of lower limb amputations with the type 2 diabetes drugs Invokana and Invokamet to include other drugs in the class. Invokana and Invokamet contain the active ingredient canagliflozin, which is in a class called sodium glucose cotransporter 2 (SGLT2) inhibitors. The EMA’s investigation will now also focus on other SGLT2 inhibitors such as dapagliflozin (which includes the brand names Farxiga and Xigduo XR) and empagliflozin (which includes the brand name Jardiance). The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) launched a safety review on canagliflozin in ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.